G3T Therapeutics
- Home
- Companies
- G3T Therapeutics
- Products
- G3T - Model PILLAR 2 - Deep Panomic ...
G3T - Model PILLAR 2 - Deep Panomic Molecular Profiling Pharmaceutical Pipeline
FromG3T Therapeutics
Using today`s technologies we have the capability to measure every molecule in the blood that can be measured. We perform the following measurements and combine the results with deep, quantitative phenotypic data:
Most popular related searches
genomic sequencing
insulin resistant
insulin resistance
genomics
biomarker
pharmaceuticals
genetic disease
We measure a large range of molecules
- Whole genome sequencing; ~30x (~25,000 genes; 3 billion nucleotides in each patient)
- DNA methylation analysis (~500,000 methylation sites in each patient)
- RNA sequencing:
- ~100,000 transcripts in each patient
- ~28,000 genes in each patient
- ~6,000 micro-RNA’s (miR’s) in each patient
- Unbiased mass spectrometry of:
- Proteomics: ~1,800 proteins in each patient
- Metabolomics: ~1,100 metabolites in each patient
- Lipidomics: ~150 lipid species in each patient
- “Conventional biomarkers”: we measure a large suite of over 200 “conventional” biomarkers related to inflammation, fibrosis, lipids and lipoproteins, endothelial dysfunction, insulin resistance, etc.
Why do we use whole genome sequencing?
Because over 93% of disease-associated genetic variants are in the non-coding portion of the genome.
Why do we use “panomic” approach, not just whole genome sequencing?
Because taken together, known genetic variants cannot explain more than 5-10% of a disease trait/phenotype.